Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

TrovaGene Inc. (TROV)

1.0081   -0.002 (-0.19%) 10-15 09:32
Open: 1.05 Pre. Close: 1.01
High: 1.0081 Low: 1
Volume: 3,411 Market Cap: 6M
TrovaGene Inc is clinical-stage, precision medicine oncology therapeutics company. Its focus is to develop oncology therapeutics for improved cancer care and to optimize drug development by leveraging its Precision Cancer Monitoring technology.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.077 - 1.087 1.087 - 1.094
Low: 0.891 - 0.903 0.903 - 0.91
Close: 0.995 - 1.016 1.016 - 1.029

Technical analysis

as of: 2019-10-14 4:49:18 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 1.95     One year: 2.50
Support: Support1: 0.91    Support2: 0.76
Resistance: Resistance1: 1.67    Resistance2: 2.14
Pivot: 1.31
Moving Average: MA(5): 1.10     MA(20): 1.41
MA(100): 2.09     MA(250): 3.15
MACD: MACD(12,26): -0.21     Signal(9): -0.18
Stochastic oscillator: %K(14,3): 7.84     %D(3): 6.06
RSI: RSI(14): 23.61
52-week: High: 9.65  Low: 0.91  Change(%): -82.3
Average Vol(K): 3-Month: 46662  10-Days: 20841

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
TROV has closed above bottom band by 5.1%. Bollinger Bands are 9.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Trovagene's Onvansertib Shows Response in Phase Ib AML Study
Trovagene (TROV) successfully completes a phase Ib study, evaluating onvansertib in combination with standard-of-care in AML patients. The regimen is well tolerated and safe.

TrovaGene, Inc. (NASDAQ:TROV) - TrovaGene Shares Volatile Ahead of Oncology Presentation
TrovaGene Inc (NASDAQ: TROV) shares, which had been on a downtrend since early April, reversed course in mid-August. From an intraday low of $1.30 on …

Financial Analysis

Growth NA
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability NA
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency NA
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency NA
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ Capital Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 6.18
Shares Float (M) 5.15
% Held by Insiders 1.32
% Held by Institutions 10.15
Shares Short (K) 591
Shares Short P. Month (K)

Stock Financials

EPS -3.905
Book Value (p.s.) 1.630
PEG Ratio
Profit Margin
Operating Margin -3368.74
Return on Assets (ttm) -55.1
Return on Equity (ttm) -121.2
Qtrly Rev. Growth 23.7
Gross Profit (p.s.) -1.356
Sales Per Share
EBITDA (p.s.) -2.469
Qtrly Earnings Growth
Operating Cash Flow (M) -13.90
Levered Free Cash Flow (M) -8.71

Stock Valuations

P/E -0.26
P/E Growth Ratio -0.03
P/BV 0.62
P/S 56743636.00
P/CF -0.45

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date 2019-02-20
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.